相关实验视频

Updated: Mar 6, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

瘤性病毒疗法通过吸引耐化疗旁观者CD8⁺ T细胞来加强化疗-PD-1免疫疗法

Yang Yang¹, Junjian He², Texi Liang¹

¹Guangdong Province Key Laboratory of Immune Regulation and Immunotherapy, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, Guangdong, China.

Journal for immunotherapy of cancer

|March 4, 2026

概括

这项研究确定了耐化疗CD8+ T_BYS细胞作为治疗点. 将OV-BYTE治疗与化疗相结合的向这些细胞可以增强抗瘤免疫力和疗效.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
病毒学病毒学

背景情况:

化疗和PD-1免疫检查点阻断 (ICB) 疗效受到化疗对瘤特异性CD8+ T (T_TST) 细胞的细胞毒性限制.
这项研究的目标是抗化疗的免疫细胞库,以克服这一局限性.

研究的目的:

描述CD8+ T_TST和旁观者记忆CD8+ T (T_BYS) 细胞对化疗的敏感性.
评估结合化疗和T细胞向瘤性病毒治疗 (OV-BYTE) 的抗瘤疗效.

主要方法:

使用病毒感染和瘤 (结直肠癌,黑色素瘤) 的小鼠模型.
基化疗对CD8+ T_TST和T_BYS细胞的评估细胞毒性.
在携带瘤的小鼠中评估了联合化疗和OV-BYTE治疗.
在小鼠和患者衍生模型中测试了三重组合疗法 (OV-BYTE,化疗,PD-1 ICB).

主要成果:

CD8+ T_TST细胞易受化疗,而CD8+ T_BYS细胞是静止和抗化疗的.
CD8+ T_BYS向的OV-BYTE疗法与化疗协同用于控制瘤.
这种组合恢复了CD8+ T_TST细胞功能,并改善了抗瘤功效.

结论:

抗化疗的CD8+ T_BYS细胞小区是关键的治疗点.
OV-BYTE是一种强大的药物,可以克服化疗免疫治疗的局限性.
这一策略为先进的联合癌症治疗提供了一种可翻译的方法.

关键词:

化疗化疗是一种化学疗法.免疫检查点抑制剂免疫检查点抑制剂瘤学病毒病毒.一个T细胞细胞.病毒特异性T细胞

更多相关视频

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...